Preserving the Pulse of Integrity: Sun Pharma Clinches Trademark Victory in Delhi High Court

In a significant move to protect intellectual property within the pharmaceutical sector, the High Court of Delhi has granted a permanent injunction in favor of Sun Pharmaceutical Industries Ltd. against Defendant No. 2, Biodeal Pharmaceuticals P. Ltd. The ruling brings a definitive end to a trademark dispute involving Sun Pharma’s well-established brands, 'PEPFIZ' and 'MINOZ', which had been targeted by the defendant’s unauthorized use of phonetically, visually, and structurally similar marks.

Striking at Counterfeits: The Conflict

Sun Pharmaceutical Industries Ltd., a global pharmaceutical leader, traced the roots of its 'PEPFIZ' mark back to 1991, with continuous use for medical preparations since 2004. Similarly, its 'MINOZ' mark, established in 2003, had amassed a substantial market presence with sales exceeding ₹216 million in the 2023-24 financial year.

The dispute arose after Sun Pharma discovered the proliferation of products under the marks 'PEPFIX-DSR' and 'MINOZIL', which the court found to be blatant attempts to capitalize on Sun Pharma's hard-earned brand equity.

A Case of Triple Identity

Justice Tejas Karia, in his order, underscored that this was a classic case of "triple identity." The infringing marks were not only nearly identical to the original brands; the product categories were the same, and they were funneled through identical trade channels to the same consumer base.

The court noted that the Local Commissioner’s report, which documented the seizure of approximately 19,000 infringing products at the premises of Defendant No. 2, provided irrefutable evidence of the scale of the infringement.

The Silence of the Defendant

Despite being duly served on December 22, 2024, Defendant No. 2 chose not to appear or contest the allegations. Consequently, the court proceeded ex-parte , treating the averments in the plaint as admitted. Justice Karia’s summary judgment effectively holds the defendant responsible for the unauthorized use, finding that the defendant attempted to "ride upon the goodwill and reputation" of Sun Pharma.

Protecting Consumer Trust and Brand Integrity

The implications of this judgment extend beyond the interests of the plaintiff. The court emphasized that such infringing activities carry the potential to deceive unsuspecting patients by directing them toward inferior-quality products, which poses a significant public health risk.

Key Observations

The court’s reasoning highlights the necessity of strict trademark enforcement:

• "This is a case of triple identity, where the Plaintiff’s Marks and the Impugned Mark are identical, the product category is identical and the trade channel as also the consumer base is identical."
• "To an unwary consumer of average intelligence and imperfect recollection, the Impugned Marks and the Plaintiff’s Marks are likely to appear identical, leading to confusion and deception as to the source, origin or association of the products under the Impugned Marks."
• "Defendant No. 2 has attempted to ride on the immense and valuable goodwill and reputation enjoyed by the Plaintiff, but is also attempting to show association or nexus with the Plaintiff, where none exists."
• "There is a strong likelihood that unwary consumers will be duped into buying the infringing products... which is detrimental to not only the reputation and goodwill of the Plaintiff, but is also detrimental to the consumers as they are being deceived into buying inferior quality products."

Final Decree

The Delhi High Court has formally decreed the suit, restraining the defendants from using the 'PEPFIX-DSR' or 'MINOZIL' marks in any form. Furthermore, the court has directed the defendant to bear the costs of the litigation, reinforcing the principle that parties cannot treat trademark infringement as a cost-free business strategy. This judgment serves as a stern reminder to rogue market participants that the court will not tolerate the dilution of recognized pharmaceutical brands.